Tradestie Institutional Equity Comparison Engine

RNAZ vs FEMY โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

RNAZ Overall Edge

RNAZ Captures Institutional Edge (1โ€“1 Pillars ยท 5โ€“2 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to TransCode Therapeutics, Inc. Common Stock (RNAZ) driven by superior Growth & Margin while FEMY counters with relative strength in Momentum & Technical. Fundamentally, RNAZ trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus FEMY at N/M Forward P/E and -763.9% operating margin (-18.9% YoY). In options structure, RNAZ sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against FEMY sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).

Valuation Winner Tie
RNAZ N/M vs FEMY N/M Fwd P/E
Growth & Margin Winner RNAZ
Op Margin 0.0% vs -763.9% ยท YoY +0.0% vs -18.9%
Momentum & Technical Winner FEMY
1Y -85.6% vs +54.8% ยท 52W Pos 0% vs 17%
Options & Structure Winner Tie
UNCLASSIFIED (N/A IV) vs UNCLASSIFIED (N/A IV)
RNAZ NASDAQ
TransCode Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$1.35
+2.27% 1D
Market Cap $22.3M
1M Return -20.59%
1Y Return -85.64%
Forward P/E N/M
Unified AI Score
50.3 / 100 HOLD
Tech 53.0 Fund 48.0 Flow 50.0 Mom 60.0
FEMY NASDAQ
Femasys Inc. Common Stock
Surgical & Medical Instruments & Apparatus
$1.28
-9.86% 1D
Market Cap $11.9M
1M Return -22.42%
1Y Return +54.78%
Forward P/E N/M
Unified AI Score
52.6 / 100 HOLD
Tech 61.0 Fund 62.0 Flow 50.0 Mom 64.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: RNAZ -85.64% FEMY +54.78% Spread: +138.75 pp (FEMY Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
RNAZ TTM Op. Margin: 0.0% FEMY TTM Op. Margin: -763.9%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on RNAZ vs FEMY. Trailing 12-month operating profitability (RNAZ 0.0% vs FEMY -763.9%) and valuation multiples (RNAZ N/M vs FEMY N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: RNAZ (5) vs FEMY (2)
Institutional Metric RNAZ FEMY Criterion Row Winner
Market Capitalization Scale $22.3M $11.9M Larger Scale RNAZ
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth +0.0% -18.9% Higher Growth RNAZ
Operating Margin (TTM) Profitability 0.0% -763.9% Higher Margin RNAZ
Net Profit Margin Profitability 0.0% 0.0% Higher Margin Tie
Return on Equity (ROE) Capital Efficiency -59.3% -425.0% Higher ROE RNAZ
52-Week Range Position Momentum 0% ($1โ€“$13) 17% ($0โ€“$6) Stronger Trend FEMY
Beta / 30D Volatility Risk Regime 0.96ฮฒ ยท 63% Vol 4.01ฮฒ ยท 72% Vol Lower Realized Risk RNAZ
Unified Institutional Score Composite Signal 50.3 / 100 (HOLD) 52.6 / 100 (HOLD) Higher Composite FEMY

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full RNAZ vs FEMY Buy Guide
RNAZ UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live RNAZ Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
FEMY UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live FEMY Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither RNAZ nor FEMY registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.